113 related articles for article (PubMed ID: 29753168)
1. Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma.
Mashayekhi F; Saberi A; Mashayekhi S
Clin Neurol Neurosurg; 2018 Jul; 170():84-87. PubMed ID: 29753168
[TBL] [Abstract][Full Text] [Related]
2. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
[TBL] [Abstract][Full Text] [Related]
3. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
4. Presence of matrix metalloproteinase-2 and tissue inhibitor matrix metalloproteinase-2 gene polymorphisms and immunohistochemical expressions in intracranial meningiomas.
Coven İ; Ozer O; Ozen O; Şahin Fİ; Altinors N
J Neurosurg; 2014 Dec; 121(6):1478-82. PubMed ID: 25259564
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer.
Komorowski J; Pasieka Z; Jankiewicz-Wika J; Stepień H
Thyroid; 2002 Aug; 12(8):655-62. PubMed ID: 12225633
[TBL] [Abstract][Full Text] [Related]
6. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
9. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
10. Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas.
Benassi MS; Magagnoli G; Ponticelli F; Pazzaglia L; Zanella L; Gamberi G; Ragazzini P; Ferrari C; Mercuri M; Picci P
Histol Histopathol; 2003 Oct; 18(4):1035-40. PubMed ID: 12973672
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Hepatocyte growth factor and its soluble receptor (s-cMet) in the serum of patients with different grades of meningioma.
Mashayekhi F; Sasani ST; Saberi A; Salehi Z
J Clin Neurosci; 2021 Nov; 93():1-5. PubMed ID: 34656230
[TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitors of matrix metalloproteinases in serum are cardiac biomarkers in Emery-Dreifuss muscular dystrophy.
Niebroj-Dobosz IM; Sokołowska B; Madej-Pilarczyk A; Marchel M; Hausmanowa-Petrusewicz I
Kardiol Pol; 2015; 73(5):360-5. PubMed ID: 25563468
[TBL] [Abstract][Full Text] [Related]
15. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
Komosinska-Vassev K; Olczyk P; Winsz-Szczotka K; Kuznik-Trocha K; Klimek K; Olczyk K
Gerontology; 2011; 57(1):44-52. PubMed ID: 20215736
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
17. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover.
Phillips PA; McCarroll JA; Park S; Wu MJ; Pirola R; Korsten M; Wilson JS; Apte MV
Gut; 2003 Feb; 52(2):275-82. PubMed ID: 12524413
[TBL] [Abstract][Full Text] [Related]
18. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
19. Investigating the Levels of Soluble Extracellular Domain of HER2 Protein in the Sera of Meningioma Patients.
Abtahi S; Hakimrabet S; Malekzadeh M; Deghanian AR; Ghaderi A
Turk Neurosurg; 2019; 29(1):9-13. PubMed ID: 29384187
[TBL] [Abstract][Full Text] [Related]
20. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
